U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    109.32
    +0.89 (+0.82%)
     
  • Gold

    1,806.30
    +4.80 (+0.27%)
     
  • Silver

    19.78
    +0.19 (+0.96%)
     
  • EUR/USD

    1.0457
    +0.0031 (+0.29%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • GBP/USD

    1.2160
    +0.0057 (+0.47%)
     
  • USD/JPY

    135.3210
    +0.1460 (+0.11%)
     
  • BTC-USD

    19,791.65
    +694.93 (+3.64%)
     
  • CMC Crypto 200

    428.08
    +7.94 (+1.89%)
     
  • FTSE 100

    7,250.89
    +82.24 (+1.15%)
     
  • Nikkei 225

    26,153.81
    +218.19 (+0.84%)
     

Why Cellectis' Shares Rose 22.7% This Week

·2 min read
Why Cellectis' Shares Rose 22.7% This Week
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Cellectics (NASDAQ: CLLS), a clinical-stage biopharmaceutical company that specializes in oncology, rose 22.7% this week, according to data from S&P Global Market Intelligence. The company released research data on its new universal CAR (Chimeric Antigen Receptors) T-cell HEAL platform at The American Society of Gene and Cell Therapy's (ASGCT) annual meeting on Monday. In the report, the company said its novel immune-evasive CAR T-cell (ΔTRACCARΔB2MHLAE) showed preclinical promise in fighting acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).